Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Indaptus Therapeutics (INDP)
NASDAQ:INDP
RESEARCH TOOLSreports
Holding INDP?
Track your performance easily
INDP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.02 - $3.10
Previous Close$1.05
Volume102.44K
Average Volume (3M)110.75K
Market Cap
$10.66M
Enterprise Value$3.38M
Total Cash (Recent Filing)$7.38M
Total Debt (Recent Filing)$107.99K
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Mar 13, 2025EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding10,196,884
10 Day Avg. Volume21,779
30 Day Avg. Volume110,755
Standard Deviation0.21
R-Squared0.17
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)1.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$5.00Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Indaptus Therapeutics News
Ownership Overview
15.52% Insiders
3.05% Mutual Funds
1.66% Other Institutional Investors
77.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INDP FAQ
What was Indaptus Therapeutics’s price range in the past 12 months?
Indaptus Therapeutics lowest stock price was $1.02 and its highest was $3.10 in the past 12 months.
What is Indaptus Therapeutics’s market cap?
Currently, no data Available
When is Indaptus Therapeutics’s upcoming earnings report date?
Indaptus Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 110 days.
How were Indaptus Therapeutics’s earnings last quarter?
Indaptus Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.48 by $0.16.
Is Indaptus Therapeutics overvalued?
According to Wall Street analysts Indaptus Therapeutics’s price is currently Undervalued.
Does Indaptus Therapeutics pay dividends?
Indaptus Therapeutics does not currently pay dividends.
What is Indaptus Therapeutics’s EPS estimate?
Indaptus Therapeutics’s EPS estimate is -$0.44.
How many shares outstanding does Indaptus Therapeutics have?
Indaptus Therapeutics has 10,196,884 shares outstanding.
What happened to Indaptus Therapeutics’s price movement after its last earnings report?
Indaptus Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.48. Following the earnings report the stock price went down -4.959%.
Which hedge fund is a major shareholder of Indaptus Therapeutics?
Currently, no hedge funds are holding shares in INDP
---
Indaptus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (400.00% Upside)
$5.00 (400.00% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.00%
12-Months-Change
Fundamentals
Return on Equity
-139.60%
Trailing 12-Months
Asset Growth
-53.69%
Trailing 12-Months
Company Description
Indaptus Therapeutics
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company engaging in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.
---
INDP Stock 12 Month Forecast
Average Price Target
$5.00
▲(400.00% Upside)
Technical Analysis
TRACON Pharmaceuticals
―
Cellectar Biosciences
―
Oncternal Therapeutics
―
TuHURA Biosciences
―
Best Analysts Covering INDP
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-31.92%
reiterated a buy rating 11 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -31.92% per trade.
---